Open Interest and Volume Dynamics
On 7 July 2026, Zydus Lifesciences Ltd (symbol: ZYDUSLIFE) recorded an open interest (OI) of 20,364 contracts in its derivatives, marking a substantial increase of 3,508 contracts or 20.81% compared to the previous OI of 16,856. This sharp rise in OI is accompanied by a trading volume of 23,597 contracts, indicating robust participation from traders and investors alike.
The futures segment alone accounted for a value of approximately ₹17,571.19 lakhs, while the options segment’s notional value stood at an impressive ₹23,851.61 crores. The combined derivatives turnover reached ₹21,717.63 lakhs, underscoring the heightened liquidity and interest in Zydus Lifesciences’ contracts.
Price Performance and Technical Strength
The underlying stock price has been on a steady ascent, hitting a new 52-week high of ₹1,181.5 on the same day. This represents a 2.47% intraday gain and a 1.67% return over the day, outperforming the Pharmaceuticals & Biotechnology sector’s 0.57% gain and the broader Sensex’s decline of 0.44%. Notably, the stock has recorded four consecutive days of gains, delivering a cumulative return of 6.7% during this period.
Technical indicators reinforce the bullish sentiment, with Zydus Lifesciences trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Such a consistent uptrend across multiple timeframes highlights strong investor confidence and momentum.
Investor Participation and Liquidity
Investor engagement has also surged, as evidenced by the delivery volume of 11.76 lakh shares on 7 July, which is 49.31% higher than the five-day average delivery volume. This increase in delivery volume suggests genuine accumulation rather than speculative trading, a positive sign for medium to long-term investors.
Liquidity remains ample, with the stock’s average traded value supporting trade sizes of up to ₹3.53 crores based on 2% of the five-day average traded value. This ensures that institutional and retail investors can transact sizeable positions without significant market impact.
Just announced: This Small Cap from Tyres & Allied with precise target price is our pick for the week. Get the pre-market insights that informed this selection!
- - Just announced pick
- - Pre-market insights shared
- - Tyres & Allied weekly focus
Market Positioning and Directional Bets
The surge in open interest alongside rising volumes and price gains suggests that market participants are increasingly positioning for an upward move in Zydus Lifesciences. The 20.81% increase in OI is indicative of fresh long positions being established rather than short covering, given the concurrent price appreciation and volume expansion.
Options market data, with a notional value exceeding ₹23,851 crores, further supports this view. The elevated options activity often reflects hedging strategies and directional bets, with traders likely favouring call options to capitalise on anticipated upside potential.
Such positioning aligns with the company’s strong fundamentals and positive sectoral outlook. Zydus Lifesciences, operating in the Pharmaceuticals & Biotechnology industry, benefits from robust demand drivers including increasing healthcare expenditure and innovation in drug development.
Mojo Score Upgrade and Analyst Sentiment
Reflecting the improved market outlook, Zydus Lifesciences’ Mojo Score has been upgraded to 80.0, earning a “Strong Buy” grade as of 6 July 2026, up from a previous “Buy” rating. This upgrade signals enhanced confidence in the stock’s growth prospects and risk-reward profile.
The company’s mid-cap market capitalisation of ₹1,16,967 crores positions it well within the pharmaceutical sector, balancing growth potential with relative stability. The upgrade is supported by favourable technical trends, rising investor participation, and solid financial metrics.
Thinking about Zydus Lifesciences Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this mid-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Implications for Investors
For investors, the confluence of rising open interest, strong volume, and positive price momentum in Zydus Lifesciences suggests a favourable entry point. The stock’s outperformance relative to its sector and the broader market, combined with technical strength across multiple moving averages, supports a bullish stance.
However, as with all mid-cap stocks, investors should remain mindful of volatility risks and monitor broader market conditions. The pharmaceutical sector can be sensitive to regulatory developments and global health trends, which may impact stock performance.
Given the current data, market participants appear to be positioning for continued gains, with fresh long positions and call option activity signalling confidence in the stock’s near-term trajectory.
Summary
Zydus Lifesciences Ltd’s recent surge in open interest by over 20%, coupled with strong volume and price gains, highlights a significant shift in market positioning towards bullish bets. The stock’s technical and fundamental indicators, alongside an upgraded Mojo Score to “Strong Buy,” reinforce the positive outlook. Investors should consider this momentum while balancing sector-specific risks and market volatility.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
